Introduction
G protein-coupled receptors (GPCRs), also known as 7-transmembrane (7TM) domain receptors, comprise the largest and most diverse gene super-family in humans->1% of the total protein-coding human genome. Estimates of the exact number of GPCR genes vary but a recent phylogenetic analysis identified over 800 (1) . Of these, 701 were classified within the rhodopsin family (type A) including 241 non-olfactory receptors. Many protein coding genes are alternatively spliced giving rise to isoforms so the true number of functionally unique receptors may be much higher than estimates based on gene numbers.
These GPCRs sense extracellular molecules and, through their interaction with G proteins, activate downstream signal transduction pathways. GPCRs respond to a huge range of stimuli, including light, odours, hormones, neurotransmitters and peptides (2) . GPCRs represent around half of cell surface drug targets (3) and are a very successful therapeutic target family for the pharmaceutical industry accounting for the majority of best-selling drugs, 30% of all prescription pharmaceuticals on the market (4). The potential for further exploitation remains high, as only 10% of GPCRs are targeted by these marketed drugs (5) .
Reactome is a free, open-source pathways database. Information in Reactome is captured by expert curators and peer-reviewed by experts in their fields of biology. The data is extensively cross-referenced to databases such as Ensembl [http://www.ensembl.org/index.html (6) to further expand the data richness. Tools are available in Reactome to help users with analyses such as pathway over-representation (enrichment) and pathway differential expression, and data including tables of pairwise proteinprotein interactions computed from manually curated reactions and complexes can be downloaded in a range of formats.
Several resources hold rich data for GPCRs. UniProt is a comprehensive protein knowledgebase of protein sequence and functional information. IUPHAR-db (International Union of basic and clinical PHARmacology, http://www.iuphar-db.org/) is a database of receptor nomenclature and drug classification. Its GPCR section is arranged according to the sequence homology and functional similarity of these receptors. It also contains orphan GPCR lists. These resources were used as a starting point to catalogue the GPCR project in Reactome.
Materials and methods
In UniProt, a query was constructed to search for all manually annotated and reviewed human GPCRs.
Information in Reactome is annotated by database curators. These in-house experts systematically reviewed the literature for the three GPCR families. GPCRs whose ligands were identified from published experimental data were captured via the Curator Tool, an interface which allows the curator to annotate and structure data in accord with Reactome's frame-based data model, and commit the results to a central repository (11 
Results
From UniProt, we retrieved records for the three main families of human GPCRs with the query:
family: 'G-protein coupled receptor' and organism:human and reviewed: yes
The query resulted in 836 protein matches. Of these, 797 proteins matched the three main families (A/1, B/2 and C/3). We then queried IUPHAR-db and searched published literature to identify ligands for these proteins, with the results Class A/1-726 UniProt records; ligands found for 519 Class B/2-49 UniProt records; ligands found for 29 Class C/3-22 UniProt records; ligands found for 15 Tables 1 (Class A/1) and 2 (classes B/2 and C/3) show the GPCRs, their gene names and accession numbers, and the G protein with which each one interacts.
Of 797 GPCRs in families A/1-C/3 screened from UniProt, we were able to catalogue 563 GPCRs that have ligands (70%), supported by information from IUPHAR and appropriate literature references.
We believe the remainder (234) to be true orphans i.e. no credible endogenous ligands have been determined for these receptors.
The project can be viewed here: http://www.reactome.org/cgi-bin/eventbrowser?DB=gk_ current&ID=372790
An on-line description of the features of these web pages and of additional pathway analysis tools that can be applied to the data is available here: http://www.reactome.org/userguide/Usersguide.html For each class, there are further subdivisions of the hierarchy, organized into ligand types that bind particular GPCRs. ..................................................................................................................................................................................................................................................................................... (12) . A total of 563 ligand-binding GPCRs were identified and included in Reactome; an additional 234 with no identifiable ligand were not. Notably, we included a set of GPCRs thought to function as olfactory receptors. In many cases, these GPCRs have been identified and classified based on their interaction when expressed in a model cultured cell with members of a small set of standard test odorant molecules. These studies are generally accepted as establishing the olfactory receptor function of these GPCRs, albeit without identifying the odorant molecule(s) with which they interact under physiological conditions (13) .
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Though the absence of any identified ligand presents problems for the pharmaceutical industry and for researchers wishing to study a receptor using a tool agonist, orphan receptors can be of interest when linked to a particular subcellular location and/or physiological process. For instance, the predominantly dorsal root ganglion expressed MRGX family of receptors have been extensively studied because of their narrow and therapeutically interesting expression profile (14) . The pathway contexts provided by Reactome annotation provide an additional functional grouping that may be useful in generating testable hypotheses about roles of orphan GPCRs.
Orphan GPCRs have been the subject of intensive research including ligand screening by pharmaceutical companies for many years (15, 16) , so why do so many GPCRs have no identified ligand? There are several reasons why the endogenous ligands are still undetermined for some orphan GPCRs:
They may be accessory proteins that enable another GPCR to function. The classic example of this is the GABAB receptor, which functions as an obligate dimer (17) . Dimerization may be the minimum functional state of GPCRs (18) and heterodimers may be common. Some orphan receptors may only be functional when they form a heterodimer. This adds a level of complexity that has not been systematically addressed by ligand screening because of the difficulties inherent in simultaneously expressing two receptors.
They themselves may need an as yet unknown accessory protein to respond to their ligand. The prime example of this is the amylin (AMY) receptor which is a dimer composed of a calcitonin receptor and one of three RAMPs to create AMY1-3 receptors (19, 20) . Other examples of accessory proteins that modify receptor surface expression include the REEP and RTPs (21). They may not signal via G proteins i.e. they may have some other downstream effector. There are numerous examples of GPCR signalling that is independent of G proteins (22) ; a receptor that only signals via these mechanisms is unlikely to be identified by a ligand screening exercise using any of the established technologies. They may require the presence of an accessory protein for successful signalling (23) that is not present in the assay systems routinely used for ligand identification. Ligand screening platforms used to date are unable to detect G12/13 coupled receptors, indeed G12/13 signalling is rarely measured directly, but inferred from remote downstream events (24) . The G12/13 signalling route has only recently been studied in any detail (25) so perhaps a portion of orphans fall into this category. This point could be extended to suggest that none of the ligand screening technologies are optimal for every receptor subtype. It could be that some ligand-receptor interactions have been missed because the signal was not detectable using the technology available. Newly emerging technologies such as Surface Plasmon Resonance may help to address this (26) .
Overlaying protein-protein interaction data e.g. from IntAct on the curated Reactome GPCR dataset may provide a powerful approach for identifying candidate heterodimer partners and their potential functions and thus provides a novel tool for the study of orphan receptors (27) . Overlaying protein-small molecule data from resources such as PubChem, ChEMBL or proprietary sources may enable identification of cofactors or modulators and could identify novel lead compounds.
Reactome contains several tools for the analysis of large-scale data sets that the user can submit to the resource. Results of such analyses are exportable in many formats from PNG images to systems biology data standards such as BioPAX and SBML. Some key features of the data in Reactome are: data in Reactome is free and open-source data can be analysed by the 'Skypainter' tool in Reactome to perform pathway enrichment analysis or expression analysis Reactome contains orthologue predictions to many model organisms, providing a template for analysing structure-function conservation in GPCR gene families across species ........................................................................................................................................................................................................................................................................................ .......................................................................................................................................................................................................................................................................................... bulk querying of Reactome data can be easily performed using the 'BioMart' tool.
Features accessed from the pathway diagrams page (Entity Level Views or ELVs) Protein: Protein interaction overlays could potentially provide researchers with a starting point for novel drug targets Protein: drug interaction overlays could help to distinguish potentially useful drugs that act on a narrow range of similar processes from ones likely to have adverse effects because they interact with many proteins or with proteins involved in a diverse range of processes.
